BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, Uemura N, Katsuyama T, Fukuda Y, Haruma K. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol. 2007;45:4006-4010. [PMID: 17942652 DOI: 10.1128/jcm.00740-07] [Cited by in Crossref: 119] [Cited by in F6Publishing: 130] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 Inose R, Muraki Y, Kamimoto Y, Kusama Y, Koizumi R, Yamasaki D, Ishikane M, Tanabe M, Ohmagari N. The intended purpose and regional patterns of use of antibiotics for managing Clostridioides (Clostridium) difficile infections: An analysis of the National Database of Health Insurance Claims and Specific Health Checkups data of Japan. J Infect Chemother 2021:S1341-321X(21)00340-8. [PMID: 34916136 DOI: 10.1016/j.jiac.2021.12.004] [Reference Citation Analysis]
2 Hsieh MS, Kuo FC, Wu MC, Wang JW, Liu CJ, Chu NS, Tsai PY, Hsu PI, Wu IC, Wu JY, Wu DC, Yu FJ, Kuo CH. Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial. J Formos Med Assoc 2021:S0929-6646(21)00483-6. [PMID: 34836662 DOI: 10.1016/j.jfma.2021.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sugimoto M, Murata M, Iwata E, Nagata N, Itoi T, Kawai T. Risk of Reflux-Related Symptoms and Reflux Esophagitis after Helicobacter pylori Eradication Treatment in the Japanese Population. J Clin Med 2021;10:1434. [PMID: 33916067 DOI: 10.3390/jcm10071434] [Reference Citation Analysis]
4 Furuta T. II. Problems of Eradication Therapy for <i>Helicobacter Pylori</i> in Japan. J Jpn Soc Intern Med 2021;110:20-28. [DOI: 10.2169/naika.110.20] [Reference Citation Analysis]
5 Rojas García P, van der Pol S, van Asselt ADI, Postma M, Rodríguez-Ibeas R, Juárez-Castelló CA, González M, Antoñanzas F. Efficiency of Diagnostic Testing for Helicobacter pylori Infections-A Systematic Review. Antibiotics (Basel) 2021;10:55. [PMID: 33430005 DOI: 10.3390/antibiotics10010055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Kim YM, Lee KH, Kim JH, Park SY, Song YG, Jeon SY, Park H. Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori? Antibiotics (Basel) 2020;9:E589. [PMID: 32916937 DOI: 10.3390/antibiotics9090589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K. Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. J Clin Med 2020;9:E543. [PMID: 32079208 DOI: 10.3390/jcm9020543] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
8 Topi S, Santacroce L, Bottalico L, Ballini A, Inchingolo AD, Dipalma G, Charitos IA, Inchingolo F. Gastric Cancer in History: A Perspective Interdisciplinary Study. Cancers (Basel) 2020;12:E264. [PMID: 31978985 DOI: 10.3390/cancers12020264] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
9 Asenov Angelov T, Dimitrova Kovacheva-slavova M, Ilianov Iliev H, Yankov Valkov H, Georgiev Vladimirov B. Helicobacter pyloriInfection. Gastritis - New Approaches and Treatments 2019. [DOI: 10.5772/intechopen.86963] [Reference Citation Analysis]
10 Ikuse T, Blanchard TG, Czinn SJ. Inflammation, Immunity, and Vaccine Development for the Gastric Pathogen Helicobacter pylori. Curr Top Microbiol Immunol 2019;421:1-19. [PMID: 31123883 DOI: 10.1007/978-3-030-15138-6_1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
11 Mori H, Suzuki H, Omata F, Masaoka T, Asaoka D, Kawakami K, Mizuno S, Kurihara N, Nagahara A, Sakaki N, Ito M, Kawamura Y, Suzuki M, Shimada Y, Sasaki H, Matsuhisa T, Torii A, Nishizawa T, Mine T, Ohkusa T, Kawai T, Tokunaga K, Takahashi S. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therap Adv Gastroenterol. 2019;12:1756284819858511. [PMID: 31320930 DOI: 10.1177/1756284819858511] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
12 Deguchi H, Uda A, Murakami K. Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database. Digestion 2020;101:441-9. [PMID: 31216549 DOI: 10.1159/000500819] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
13 Yokota N, Ae R, Amenomori M, Kitagawa K, Nakamura T, Yokota T, Masato K, Sasahara T, Matsubara Y, Kosami K, Nakamura Y. Clinical background factors affecting outcomes of Helicobacter pylori eradication therapy in primary care. J Gen Fam Med 2019;20:139-45. [PMID: 31312580 DOI: 10.1002/jgf2.245] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kusunoki M, Yuki M, Ishitobi H, Kobayashi Y, Nagaoka M, Takahashi Y, Fukuba N, Komazawa Y, Shizuku T, Kinoshita Y. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication. Intern Med 2019;58:1549-55. [PMID: 30713328 DOI: 10.2169/internalmedicine.2233-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24(40): 4548-4553 [PMID: 30386104 DOI: 10.3748/wjg.v24.i40.4548] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
16 Chen X, Hu L, Wu H, Liu W, Chen S, Zhou A, Liu Y. Anti-Helicobacter pylori and Anti-Inflammatory Effects and Constituent Analysis of Modified Xiaochaihutang for the Treatment of Chronic Gastritis and Gastric Ulcer. Evid Based Complement Alternat Med 2018;2018:6810369. [PMID: 29681980 DOI: 10.1155/2018/6810369] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Kashani N, Talebi Bezmin Abadi A. Comment on "First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin". Gastroenterol Res Pract 2018;2018:5173904. [PMID: 29676395 DOI: 10.1155/2018/5173904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Bachir M, Allem R, Tifrit A, Medjekane M, Drici AE, Diaf M, Douidi KT. Primary antibiotic resistance and its relationship with cagA and vacA genes in Helicobacter pylori isolates from Algerian patients. Braz J Microbiol. 2018;49:544-551. [PMID: 29452847 DOI: 10.1016/j.bjm.2017.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
19 Ji Y, Lu H. Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment. PLoS One 2018;13:e0189888. [PMID: 29370199 DOI: 10.1371/journal.pone.0189888] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
20 Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354-361. [PMID: 29138921 DOI: 10.1007/s00535-017-1407-1] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 16.4] [Reference Citation Analysis]
21 Angol DC, Ocama P, Ayazika Kirabo T, Okeng A, Najjingo I, Bwanga F. Helicobacter pylori from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. Biomed Res Int. 2017;2017:5430723. [PMID: 28555193 DOI: 10.1155/2017/5430723] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
22 Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol 2017;7:168. [PMID: 28529929 DOI: 10.3389/fcimb.2017.00168] [Cited by in Crossref: 68] [Cited by in F6Publishing: 75] [Article Influence: 13.6] [Reference Citation Analysis]
23 Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 2017; 23(4): 668-675 [PMID: 28216974 DOI: 10.3748/wjg.v23.i4.668] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
24 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1565] [Cited by in F6Publishing: 1657] [Article Influence: 313.0] [Reference Citation Analysis]
25 Ikuse T, Kudo T, Obayashi N, Jimbo K, Aoyagi Y, Ohtsuka Y, Blanchard TG, Czinn SJ, Shimizu T. A Retrospective Analysis of Three Non-Invasive Tests for Initial Diagnosis of &lt;i&gt;Helicobacter pylori&lt;/i&gt; Infection in Children. AiM 2017;07:253-264. [DOI: 10.4236/aim.2017.74021] [Reference Citation Analysis]
26 Ikuse T, Aoyagi Y, Obayashi N, Jimbo K, Kudo T, Ohtsuka Y, Blanchard TG, Czinn SJ, Shimizu T. Antibiotic Resistance of &lt;i&gt;Helicobacter pylori&lt;/i&gt; and Eradication Rate in Japanese Pediatric Patients. AiM 2017;07:241-252. [DOI: 10.4236/aim.2017.74020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Kim GH. Status ofHelicobacter pyloriEradication in Japan. Korean J Helicobacter Up Gastrointest Res 2017;17:4. [DOI: 10.7704/kjhugr.2017.17.1.4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Lee JY, Park KS. Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol Res Pract 2016;2016:9086581. [PMID: 28070184 DOI: 10.1155/2016/9086581] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
29 Goudarzi M, Heidary M, Azad M, Fazeli M, Goudarzi H. Evaluation of antimicrobial susceptibility and integron carriage in Helicobacter pylori isolates from patients. Gastroenterol Hepatol Bed Bench 2016;9:S47-52. [PMID: 28224028] [Reference Citation Analysis]
30 Miftahussurur M, Syam AF, Nusi IA, Makmun D, Waskito LA, Zein LH, Akil F, Uwan WB, Simanjuntak D, Wibawa ID, Waleleng JB, Saudale AM, Yusuf F, Mustika S, Adi P, Maimunah U, Maulahela H, Rezkitha YA, Subsomwong P, Nasronudin, Rahardjo D, Suzuki R, Akada J, Yamaoka Y. Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. PLoS One. 2016;11:e0166199. [PMID: 27906990 DOI: 10.1371/journal.pone.0166199] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
31 Liu AR, Du YQ. Current status of Helicobacter pylori infection and evolution of treatment strategy in China. Shijie Huaren Xiaohua Zazhi 2016; 24(32): 4396-4403 [DOI: 10.11569/wcjd.v24.i32.4396] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Yamada S, Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N, Nakamura H, Sato H, Okuyama Y, Kimura H, Yoshida N. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pyloriWorld J Gastrointest Pharmacol Ther 2016; 7(4): 550-555 [PMID: 27867688 DOI: 10.4292/wjgpt.v7.i4.550] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
33 Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol. 2016;16:256. [PMID: 27809767 DOI: 10.1186/s12866-016-0873-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
34 Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016;65:1439-46. [PMID: 26935876 DOI: 10.1136/gutjnl-2015-311304] [Cited by in Crossref: 201] [Cited by in F6Publishing: 210] [Article Influence: 33.5] [Reference Citation Analysis]
35 Ji Z, Han F, Meng F, Tu M, Yang N, Zhang J. The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China. Medicine (Baltimore). 2016;95:e2831. [PMID: 26937912 DOI: 10.1097/md.0000000000002831] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 5.8] [Reference Citation Analysis]
36 Miftahussurur M, Yamaoka Y. Population-Based Strategies for Helicobacter pylori-Associated Disease Management: Asian Perspective. Helicobacter pylori Research 2016. [DOI: 10.1007/978-4-431-55936-8_23] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Kwon YH. Amoxicillin. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_37] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Lee JY. Triple Therapy. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_41] [Reference Citation Analysis]
39 Lee SM. Metronidazole. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_39] [Reference Citation Analysis]
40 Zhang M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol 2015; 21(48): 13432-13437 [PMID: 26730153 DOI: 10.3748/wjg.v21.i48.13432] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
41 Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-533. [PMID: 26694080 DOI: 10.1111/apt.13497] [Cited by in Crossref: 396] [Cited by in F6Publishing: 428] [Article Influence: 56.6] [Reference Citation Analysis]
42 Ahn HJ, Lee DS. Helicobacter pylori in gastric carcinogenesis. World J Gastrointest Oncol 2015; 7(12): 455-465 [PMID: 26690981 DOI: 10.4251/wjgo.v7.i12.455] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 55] [Article Influence: 6.6] [Reference Citation Analysis]
43 Tong YF, Lv J, Ying LY, Xu F, Qin B, Chen MT, Meng F, Tu MY, Yang NM, Li YM, Zhang JZ. Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance. World J Gastroenterol 2015; 21(46): 13073-13079 [PMID: 26672777 DOI: 10.3748/wjg.v21.i46.13073] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
44 Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther 2015; 6(4): 183-198 [PMID: 26558152 DOI: 10.4292/wjgpt.v6.i4.183] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 51] [Article Influence: 7.0] [Reference Citation Analysis]
45 Humphries RM, Hindler JA. Susceptibility Test Methods: Fastidious Bacteria. Manual ofClinical Microbiology 2015. [DOI: 10.1128/9781555817381.ch74] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015;20:6068-6092. [PMID: 25856059 DOI: 10.3390/molecules20046068] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
47 Hosoda K, Shimomura H, Wanibuchi K, Masui H, Amgalanbaatar A, Hayashi S, Takahashi T, Hirai Y. Identification and characterization of a vitamin D₃ decomposition product bactericidal against Helicobacter pylori. Sci Rep 2015;5:8860. [PMID: 25749128 DOI: 10.1038/srep08860] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
48 Boltin D, Ben-Zvi H, Perets TT, Kamenetsky Z, Samra Z, Dickman R, Niv Y. Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned? J Clin Microbiol. 2015;53:522-527. [PMID: 25428158 DOI: 10.1128/jcm.03001-14] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
49 Tai WC, Lee CH, Chiou SS, Kuo CM, Kuo CH, Liang CM, Lu LS, Chiu CH, Wu KL, Chiu YC. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS One. 2014;9:e105822. [PMID: 25141137 DOI: 10.1371/journal.pone.0105822] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
50 Percival SL, Suleman L. Biofilms and Helicobacter pylori: Dissemination and persistence within the environment and host. World J Gastrointest Pathophysiol 2014; 5(3): 122-132 [PMID: 25133015 DOI: 10.4291/wjgp.v5.i3.122] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
51 Heo J, Jeon SW. Optimal treatment strategy for Helicobacter pylori: Era of antibiotic resistance. World J Gastroenterol 2014; 20(19): 5654-5659 [PMID: 24914324 DOI: 10.3748/wjg.v20.i19.5654] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
52 Vale FF, Oleastro M. Overview of the phytomedicine approaches against Helicobacter pyloriWorld J Gastroenterol 2014; 20(19): 5594-5609 [PMID: 24914319 DOI: 10.3748/wjg.v20.i19.5594] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
53 Nishida T, Tsujii M, Tanimura H, Tsutsui S, Tsuji S, Takeda A, Inoue A, Fukui H, Yoshio T, Kishida O, Ogawa H, Oshita M, Kobayashi I, Zushi S, Ichiba M, Uenoyama N, Yasunaga Y, Ishihara R, Yura M, Komori M, Egawa S, Iijima H, Takehara T. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. World J Gastroenterol 2014; 20(15): 4362-4369 [PMID: 24764674 DOI: 10.3748/wjg.v20.i15.4362] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
54 Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernandez-García T, Candia R, Bruce MG, Rabkin CS. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014;109:485-495. [PMID: 24589670 DOI: 10.1038/ajg.2014.24] [Cited by in Crossref: 108] [Cited by in F6Publishing: 116] [Article Influence: 13.5] [Reference Citation Analysis]
55 Seo SI, Kim HY. Helicobacter pylori-related Peptic Ulcer Disease. Korean J Med 2014;86:655. [DOI: 10.3904/kjm.2014.86.6.655] [Reference Citation Analysis]
56 Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol 2013; 19(45): 8168-8180 [PMID: 24363506 DOI: 10.3748/wjg.v19.i45.8168] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 76] [Article Influence: 7.4] [Reference Citation Analysis]
57 Vilaichone RK, Yamaoka Y, Shiota S, Ratanachu-ek T, Tshering L, Uchida T, Fujioka T, Mahachai V. Antibiotics resistance rate of Helicobacter pylori in Bhutan. World J Gastroenterol 2013; 19(33): 5508-5512 [PMID: 24023494 DOI: 10.3748/wjg.v19.i33.5508] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
58 Yonezawa H, Osaki T, Hanawa T, Kurata S, Ochiai K, Kamiya S. Impact of Helicobacter pylori biofilm formation on clarithromycin susceptibility and generation of resistance mutations. PLoS One. 2013;8:e73301. [PMID: 24039906 DOI: 10.1371/journal.pone.0073301] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 6.0] [Reference Citation Analysis]
59 Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes. 2013;4:541-548. [PMID: 23929066 DOI: 10.4161/gmic.25930] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
60 Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol. 2013;47:233-238. [PMID: 23090037 DOI: 10.1097/mcg.0b013e3182676e2b] [Cited by in Crossref: 33] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
61 Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013;10:495-500. [PMID: 23752823 DOI: 10.1038/nrgastro.2013.96] [Cited by in Crossref: 81] [Cited by in F6Publishing: 85] [Article Influence: 9.0] [Reference Citation Analysis]
62 Shiota S, Murakawi K, Suzuki R, Fujioka T, Yamaoka Y. Helicobacter pylori infection in Japan. Expert Rev Gastroenterol Hepatol. 2013;7:35-40. [PMID: 23265147 DOI: 10.1586/egh.12.67] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 6.8] [Reference Citation Analysis]
63 Shiota S, Nguyen LT, Murakami K, Kuroda A, Mizukami K, Okimoto T, Kodama M, Fujioka T, Yamaoka Y. Association of helicobacter pylori dupA with the failure of primary eradication. J Clin Gastroenterol. 2012;46:297-301. [PMID: 22298090 DOI: 10.1097/mcg.0b013e318243201c] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
64 Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. World J Gastrointest Pharmacol Ther 2012; 3(1): 1-6 [PMID: 22408744 DOI: 10.4292/wjgpt.v3.i1.1] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
65 Hindler JA, Jorgensen JH. Susceptibility Test Methods: Fastidious Bacteria. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, editors. Manual of Clinical Microbiology. Wiley; 2011. pp. 1180-203. [DOI: 10.1128/9781555816728.ch71] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
66 Miendje Deyi VY, Bontems P, Vanderpas J, De Koster E, Ntounda R, Van den Borre C, Cadranel S, Burette A. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol. 2011;49:2200-2209. [PMID: 21450969 DOI: 10.1128/jcm.02642-10] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 5.1] [Reference Citation Analysis]
67 Wang YC, Li WY, Wu DC, Wang JJ, Wu CH, Liao JJ, Lin CK. In vitro activity of 2-methoxy-1,4-naphthoquinone and stigmasta-7,22-diene-3β-ol from impatiens balsamina L. against multiple antibiotic-resistant Helicobacter pylori. Evid Based Complement Alternat Med. 2011;2011:704721. [PMID: 19773391 DOI: 10.1093/ecam/nep147] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
68 Shiota S, Murakami K, Fujioka T, Yamaoka Y. Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective. Expert Rev Gastroenterol Hepatol. 2010;4:149-156. [PMID: 20350262 DOI: 10.1586/egh.10.7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
69 Sasaki M, Ogasawara N, Utsumi K, Kawamura N, Kamiya T, Kataoka H, Tanida S, Mizoshita T, Kasugai K, Joh T. Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. J Clin Biochem Nutr. 2010;47:53-58. [PMID: 20664731 DOI: 10.3164/jcbn.10-10] [Cited by in Crossref: 65] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
70 Murakami K, Okimoto T, Kodama M, Tanahashi J, Fujioka T, Ikeda F, Muraoka H, Takigawa M, Saika T, Hasegawa M, Kobayashi I. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother. 2009;53:3097-3099. [PMID: 19380599 DOI: 10.1128/aac.01552-08] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
71 Xuan SH, Zhou YG, Wang HM. Advance in Helicobacter pylori resistance to clarithromycin. Shijie Huaren Xiaohua Zazhi 2008; 16(27): 3060-3064 [DOI: 10.11569/wcjd.v16.i27.3060] [Cited by in F6Publishing: 1] [Reference Citation Analysis]